In silico screening of nonsteroidal anti-inflammatory drugs and their combined action on prostaglandin H synthase-1

Pharmaceuticals

Volumn 3, Issue 7, 2010, Pages 2059-2081

  Goltsov, Alexey ^a   Lebedeva, Galina ^b   Humphery Smith, Ian ^c   Goltsov, Gregory ^b   Demin, Oleg ^d,e   Goryanin, Igor ^a,b  

^a UNIVERSITY OF ABERTAY DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Deomed   (United Kingdom)

^d Institute for Systems Biology SPb   (Russian Federation)

^e MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Aspirin resistance; COX 1,2; Kinetic modeling; NSAID; NSAID combination

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXIDASE;

ARTHRALGIA; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPUTER MODEL; CONCENTRATION (PARAMETERS); DOSE RESPONSE; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME MECHANISM; HEART INFARCTION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LOW DRUG DOSE; MICROENVIRONMENT; NONHUMAN; PREDICTION;

EID: 77955675813     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3072059     Document Type: Article

References (50)

1. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem. 2000, 69, 145-182.
2. Kulmacz, R.J.; van der Donk, W.A.; Tsai, A.L. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog. Lipid Res. 2003, 42, 377-404.
3. Tsai, A.L.; Kulmacz, R.J. Prostaglandin H synthase: Resolved and unresolved mechanistic issues. Arch. Biochem. Biophys. 2010, 493, 103-124.
4. Kulmacz, R.J. Cellular regulation of prostaglandin H synthase catalysis. FEBS Lett. 1998, 430, 154-157.
5. Rouzer, C.A.; Marnett, L.J. Cyclooxygenases: Structural and functional insights. J. Lipid Res. 2009, 50, S29-S34.
6. Bala, M.; Chin, C.N.; Logan, A.T.; Amin, T.; Marnett, L.J.; Boutaud, O.; Oates, J.A. Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem. Pharmacol. 2008, 75, 1472-1481.
7. Gierse, J.K.; Koboldt; C.M.; Walker, M.C.; Seibert, K.; Isakson, P.C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 1999, 339, 607-614.
8. Ouellet, M.; Percival, M.D. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem. J. 1995, 306, 247-251.
9. Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J. A.; Vane, J. R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 1999, 96, 7563-7568.
10. Brooks, P.; Emery, P.; Evans, J.F.; Fenner, H.; Hawkey, C.J.; Patrono, C.; Smolen, J.; Breedveld F.; Day, R.; Dougados, M.; Ehrich, E.W.; Gijon-Baños, J.; Kvien, T.K.; Van Rijswijk, M.H.; Warner, T.; Zeidler, H. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999, 38, 779-788.
11. Ouellet, M.; Riendeau, D.; Percival, M.D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Nat. Acad. Sci. USA 2001, 98, 14583-14588.
12. Callan, O.H.; So, O.-Y.; Swinney, D.C. The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J. Biol. Chem. 1996, 271, 3548-3554.
13. Mitchell, J.A.; Akarasereenont, P.; Thiemermann, C.; Flower, R.J.; Vane, J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 1994, 90, 11693-11697.
14. Kargman, A.; Wong, E.; Greig, G.M.; Falgueyret, J.P.; Cromlish, W.; Ethier, D.; Yergey, J.A.; Riendeau, D.; Evans, J.F.; Kennedy, B.; Tagari, P.; Francis, D.A.; O'Neill, G.P. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem. Pharmacol. 1996, 52, 1113-1125.
15. Burch, J.W.; Baenziger, N.L.; Stanford, N.; Majerus, P.W. Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc. Natl. Acad. Sci. USA 1978, 75, 5181-5184.
16. Rome, L.H.; Lands, W.E.M. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc. Nat. Acad. Sci. USA 1975, 72, 4863-4865.
17. Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J.A.; Vane, J.R. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 2006, 20, 2468-2475.
18. Grosser, T.; Fries, A.; FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 2006, 116, 4-15.
19. Sciulli, M.G.; Renda, G.; Capone, M.L.; Tacconelli, S.; Ricciotti, E.; Manarini, S.; Evangelista, V.; Rebuzzi, A.; Patrignani, P. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. Clin. Pharmacol. Ther. 2006, 80, 115-125
20. Ben-Dor, I.; Kleiman, N.S.; Lev, E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am. J. Cardiol. 2009, 104, 227-233.
21. Folts, J.D.; Schafer, A.I.; Loscalzo, J.; Willerson, J.T.; Muller, J.E. A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials. J. Am. Coll. Cardiol. 1999, 33, 295-303.
22. Steinhubl, S.R.; Charnigo, R.; Moliterno, D.J. Resistance to antiplatelet resistance is it justified? J. Am. Coll. Cardiol. 2005, 45, 1757-1758.
23. Steinhubl, S.R. The use of anti-inflammatory analgesics in the patient with cardiovascular disease: What a pain. J. Am. Coll. Cardiol. 2005, 45, 1302-1303.
24. Blobaum, A.L.; Marnett, L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 2007, 50, 1425-1441.
25. Huntjens, D.R.; Danhof, M.; Della Pasqua, O.E. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology 2005, 44, 846-859.
26. Capone, M.L.; Sciulli, M.G.; Tacconelli, S.; Grana, M.; Ricciotti, E.; Renda, G.; Di Gregorio, P.; Merciaro, G.; Patrignani, P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J. Am. Coll. Cardiol. 2005, 45, 1295-1301.
27. Curtis, J.P.; Krumholz, H.M. The case for an adverse interaction between aspirin and non steroidal anti-inflammatory drugs: Is it time to believe the hype? J. Am. Coll. Cardiol. 2004, 43, 991-993.
28. Patrono, C.; García Rodríguez, L.A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 2005, 353, 2373-2383.
29. Goltsov, A.; Maryashkin, A.; Swat, M.; Kosinsky, Y.; Humphery-Smith, I.; Demin, O.; Goryanin, I.; Lebedeva, G. Kinetic modelling of NSAID action on COX-1: Focus on in vitro/in vivo aspects and drug combinations. Eur. J. Pharm. Sci. 2009, 36, 122-136.
30. Dietz, R.; Nastainczyk, W.; Ruf, H.H. Higher oxidation states of prostaglandin H synthase. Rapid electronic spectroscopy detected two spectral intermediates during the peroxidase reaction with prostaglandin G2. Eur. J. Biochem. 1988, 171, 321-328.
31. Wei, C.; Kulmacz, R.J.; Tsai, A.L. Comparison of branched-chain and tightly coupled reaction mechanisms for prostaglandin H synthase. Biochem. 1995, 34, 8499-8512.
32. Lu, G.; Tsai, A.L.; Van Wart, H.E.; Kulmacz, R.J. Comparison of the peroxidase reaction kinetics of prostaglandin H synthase-1 and -2. J. Biol. Chem. 1999, 74, 16162-16177.
33. Wei, C.; Timothy R. Pawelek; Kulmacz R.J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J. Biol. Chem. 1999, 274, 20301-20306.
34. Bambai, B.; Rogge, C.E.; Stec, B.; Kulmacz, R.J. Role of Asn-382 and Thr-383 in activation and inactivation of human prostaglandin H synthase cyclooxygenase catalysis. J. Biol. Chem. 2004, 279, 4084-4092.
35. Bambai, B.; Kulmacz, R.J. Prostaglandin H synthase. Effects of peroxidase cosubstrates on cyclooxygenase velocity. J. Biol. Chem. 2000, 275, 27608-27614.
36. Wu, G.; Kulmacz, R.J.; Tsai, A.L. Cyclooxygenase inactivation kinetics during reaction of prostaglandin H synthase-1 with peroxide. Biochem. 2003, 42, 13772-13777.
37. Wu, G.; Wei, C.; Kulmacz, R.J.; Osawa, Y.; Tsai, A.L. A mechanistic study of self-inactivation of the peroxidase activity in prostaglandin H synthase-1. J. Biol. Chem. 1999, 274, 9231-9237.
38. Song, I.; Ball, T.M.; Smith, W.L. Different suicide inactivation processes for the peroxidase and cyclooxygenase activities of prostaglandin endoperoxide H synthase-1. Biochem. Biophys. Res. Commun. 2001, 289, 869-875.
39. Kulmacz, R.J. Topography of prostaglandin H synthase. J. Biol. Chem. 1989, 264, 14136-14144.
40. Kulmacz, R.J.; Palmer, G.; Tsai, A.L. Prostaglandin H synthase: Perturbation of the tyrosyl radical as a probe of anticyclooxygenase agents. Mol. Pharmacol. 1991, 40, 833-837.
41. Lassmann, G.; Odenwaller, R.; Curtis, J.F.; DeGray, J.A.; Mason, R.P.; Marnett, L.J.; Eling, T.E. Electron spin resonance investigation of tyrosyl radicals of prostaglandin H synthase. Relation to enzyme catalysis. J. Biol. Chem. 1991, 266, 20045-20055.
42. Goryanin, I.; Hodgman, T.C.; Selkov, E. Mathematical simulation and analysis of cellular metabolism and regulation. Bioinformatics 1999, 15, 749-758.
43. Brash, A.R. Arachidonic acid as a bioactive molecule. J. Clin. Invest. 2001, 107, 1339-1345.
44. Sergeeva, M.G.; Varfolomeeva, A.T. Cascade of Arachidonic Acid; Public Education, Moscow, Russian, 2006.
45. Hazelton, W.D.; Tien, J.H.; Donato, V.W.; Sparks, R.; Ulrich, C.M. Prostaglandin H synthases: Members of a class of quasi-linear threshold switches. Biochem. Pharmacol. 2004, 68, 423-432.
46. Kulmacz, R.J.; Pendleton, R.B.; Lands, W.E. Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Interpretation of reaction kinetics. J. Biol. Chem. 1994, 269, 5527-5536.
47. Mbonye, U.R.; Wada, M.; Rieke, C.J.; Tang, H.Y.; Dewitt, D.L.; Smith, W.L. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum associated degradation system. J. Biol. Chem. 2006, 281, 35770-35778.
48. Mancini, J.A.; Riendea, D.; Falgueyret, J.P.; Vickers, P.J.; O'Neill, G.P. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 1995, 270, 29372-29377.
49. Gierse, J.K.; Hauser, S.D.; Creely, D.P.; Koboldt, C.; Rangwala, S.H.; Isakson, P.C.; Seibert, K. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem. J. 1995, 305, 479-484.
50. Chulada, P.C.; Langenbach, R. Differential inhibition of murine prostaglandin synthase-1 and -2 by nonsteroidal anti-inflammatory drugs using exogenous and endogenous sources of arachidonic acid. J. Pharmacol. Exp. Ther. 1997, 280, 606-613.